HIV
BMS licences phase II HIV compound festinavir
December 22, 2010Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor
Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …
Gilead’s pill shows promise in HIV prevention
November 25, 2010Research and Development, Sales and Marketing AIDS, Bill and Melinda Gates Foundation, Gilead, HIV, UN, UNAIDS, emtricitabine, tenofovir
Gilead’s HIV drug Truvada can help prevent men from contracting the disease through sexual intercourse, a new study shows.The clinical …
UN says Treatment 2.0 approach needed for AIDS
November 25, 2010Research and Development, Sales and Marketing AIDS, HIV, UN, UNAIDS
A new report on the spread of AIDS has called for the development of new pharma compounds that will lead …
FDA approves Merck’s HIV fat drug Egrifta
November 12, 2010Research and Development, Sales and Marketing EMD Serono, Egrifta, FDA, HIV, Merck KGaA, abdominal fat in HIV, tesamorelin
US regulatory authorities have approved the first treatment indicated to target abdominal fat in patients with HIV after trials showed …
Pepscan and Tibotec sign peptides deal
September 15, 2010Research and Development, Sales and Marketing CLIPS, HIV, J&J, JJ, Pepscan, Tibotec
Pepscan Therapeutics, the biotech firm focusing on protein mimicry technology has signed a deal with Tibotec. Netherlands-based Pepscan will use …
BMS factory closure could interrupt HIV drug supply
June 11, 2010Manufacturing and Production BMS, HIV, manufacturing, supply chain
Closure of a manufacturing facility in France operated by Bristol-Myers Squibb could lead to shortages of an important treatment for …
Merck’s HIV treatment fails in phase III
February 18, 2010Research and Development HIV, Merck
Merck’s HIV treatment vicriviroc has disappointed in phase III trials, and may be dropped by the company. The results failed …
New market access approach could save poorer countries millions
December 1, 2009Sales and Marketing HIV, access, developing world
An innovative approach to improving access to drugs for HIV/Aids, tuberculosis and malaria could save poorer countries millions of …
GlaxoSmithKline-Pfizer launch HIV joint venture
November 4, 2009Research and Development, Sales and Marketing GSK, HIV, Pfizer, ViiV
GlaxoSmithKline and Pfizer have launched a specialist HIV company with access to ten medicines developed by the two manufacturers.ViiV Healthcare, …
Pfizer agrees price cut in Clinton deal
September 1, 2009Research and Development, Sales and Marketing HIV, Pfizer, price cuts
Former US President Bill Clinton has brokered major new deals with Pfizer and Mylan to cut the price of tuberculosis …
Pfizer agrees price cut in Clinton deal
August 7, 2009Research and Development, Sales and Marketing HIV, Pfizer, generics
Former US President Bill Clinton has brokered major new deals with Pfizer and Mylan to cut the price of tuberculosis …
GSK and Pfizer to create HIV joint venture company
April 16, 2009Research and Development, Sales and Marketing GSK, HIV, Pfizer
The world's two biggest pharma companies are to join forces to develop and market new treatments for HIV.GlaxoSmithKline is a …
GSK: renewing the HIV pipeline
February 16, 2009Research and Development GSK, HIV
GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK …
Latest news from Datamonitor
October 13, 2008Sales and Marketing HIV
Battle for HIV drug market share getting fiercerThe HIV market, worth $9.3 billion in 2007, is expected to grow to …
Atripla approved in Europe
January 3, 2008Sales and Marketing HIV
The first ever product to combine all the drugs HIV patients need in just one daily pill has been approved …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
